- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT06894433
A neuroendoszkópos műtét hatékonysága és biztonsága a nagy intracerebrális vérzéshez (NESICH 2)
A neuroendoszkópos műtét hatékonysága és biztonsága a nagy intracerebrális vérzéshez: Multicenter, randomizált, ellenőrzött klinikai vizsgálat
This is a multicenter, randomized, controlled clinical trial comparing neuroendoscopic hematoma removal to craniotomy in the treatment of large intracerebral hemorrhage.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Previous retrospective studies have demonstrated that neuroendoscopic surgery, compared to conventional craniotomy, significantly reduces operative duration and intraoperative blood loss, enhances hematoma evacuation rates, and improves postoperative outcomes, including neurological recovery, activities of daily living, and quality of life in patients with large cerebral hemorrhage. However, there is a paucity of prospective randomized controlled trials evaluating the efficacy of different surgical techniques for intracerebral hemorrhage. To address this gap, the investigators propose a multicenter, randomized, controlled clinical trial to compare the safety and efficacy of neuroendoscopic surgery versus craniotomy, aiming to provide evidence-based guidance for surgical decision-making in cerebral hemorrhage management.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Rong Hu, MD
- Telefonszám: 8615123917123
- E-mail: huchrong@aliyun.com
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Hua Feng, MD
- Telefonszám: 8613708321681
- E-mail: fenghua201818@aliyun.com
Tanulmányi helyek
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kína, 400038
- Toborzás
- Southwest Hospital
-
Kapcsolatba lépni:
- Rong Hu, MD
- Telefonszám: 8615123917123
- E-mail: huchrong@aliyun.com
-
-
Gansu
-
Wuwei, Gansu, Kína, 733000
- Toborzás
- Wuwei People's Hospital
-
Kapcsolatba lépni:
- Lishan Ma, MD
- Telefonszám: 8613639350777
- E-mail: 779795352@qq.com
-
-
Guangxi
-
Wuzhou, Guangxi, Kína, 543001
- Toborzás
- Wuzhou Workers' Hospital
-
Kapcsolatba lépni:
- Zhongyong Deng, MD
- Telefonszám: 8613878401206
- E-mail: gxwzsgryydeng@163.com
-
-
Jilin
-
Siping, Jilin, Kína, 136000
- Toborzás
- Siping Central People's Hospital
-
Kapcsolatba lépni:
- Xiaodong Li, MD
- Telefonszám: 8613843436488
- E-mail: spszxyysjwk@sina.com
-
-
Sichuan
-
Dazhou, Sichuan, Kína, 635100
- Toborzás
- Dazhu County People's Hospital
-
Kapcsolatba lépni:
- Sheng Zhu, MD
- Telefonszám: +8615882911301
- E-mail: 371773434@qq.com
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Age 18-80 years old, male or female;
- The time between onset and admission to the first diagnostic CT is within 24 hours (for no bystanders and the time of onset is unknown, the time of the last known patient in good condition is used);
- Patients with supratentorial intracerebral hemorrhage who have obvious space-occupying effect caused by hematoma (midline structure shift > 6mm) or hematoma volume ≥ 45ml and require emergency surgery (including patients with signs of cerebral herniation such as decreased or dilated pupillary light reflex on one side);
- Before randomization, GCS score was 5-14, NIHSS score was ≥6;
- mRS Before onset: 0-1 score;
- Randomization within 24 hours after the first diagnostic CT;
- The patient or family members are informed and voluntarily sign the informed consent;
Exclusion Criteria:
- The clinical diagnosis is caused by cerebral aneurysm, cerebrovascular malformation, moyamoya disease, brain trauma, brain tumor, massive cerebral infarction hemorrhage transformation, coagulation dysfunction, etc.;
- Thalamic hemorrhage, primary ventricular hemorrhage;
- Platelet count <75×109/L, INR > 1.4;
- Patients with advanced cerebral hernia (such as dilated bifidus and no light reflex) or unstable vital signs cannot tolerate surgery;
- Irreversible brain stem impairment (eye fixation, bilateral pupil dilation), GCS≤4 points;
- Any history of parenchyma or other intracranial subarachnoid, subdural or epidural blood and surgical history in the past 30 days;
- Patients with severe advanced cognitive impairment (such as AD) or who are not expected to complete the follow-up plan as required;
- Complicated with other serious diseases: including respiratory, circulation, digestion, urinary, endocrine, immune and blood systems;
- Pregnant or breastfeeding women, or those who expect to become pregnant within one year;
- are participating in other clinical trials (excluding: observational studies that do not involve intervention, natural history and/or epidemiological studies).
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Experimental Arm
Neuroendoscopic Surgery to remove intracranial hematoma |
Subjects will receive Neuroendoscopic Surgery followed by standard medical management |
|
Aktív összehasonlító: Control Arm
Craniotomy to remove intracranial hematoma |
Subjects will receive Craniotomy followed by standard medical management |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
Időkeret: 180 days
|
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
180 days
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Length of ICU
Időkeret: Number of days from admission, up to 180 days
|
Duration of stay in the ICU |
Number of days from admission, up to 180 days
|
|
Length of hospitalization
Időkeret: Number of days from admission to discharge, up to 180 days
|
Duration of stay in the hospital |
Number of days from admission to discharge, up to 180 days
|
|
mRS Shift Analysis of Neurological Improvement Between the Two Groups
Időkeret: 180 days
|
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
180 days
|
|
mortality
Időkeret: 30 days, 90 days and 180 days
|
All cause mortality from onset to 180 days |
30 days, 90 days and 180 days
|
|
Assessment of cognitive function with Mini-Mental State Examination (MMSE)
Időkeret: 90 days and 180 days
|
The MMSE is a screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. |
90 days and 180 days
|
|
The proportion of patients with Modified Rankin Scale (mRS) score 0-3
Időkeret: 30 days and 90 days
|
Functional outcome (comparing the intervention group to the control), assessed with the modified Rankin Scale (mRS) at 6 months.The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. |
30 days and 90 days
|
|
Operation duration
Időkeret: From the beginning to the end of the surgery
|
The length of the operation |
From the beginning to the end of the surgery
|
|
Peroperative bleeding
Időkeret: During surgery
|
The amount of blood lost during surgery |
During surgery
|
|
Intraoperative blood transfusion volume
Időkeret: During surgery
|
Intraoperative blood transfusion volume |
During surgery
|
|
Incidence of rebleeding and infection
Időkeret: 3 days, 7 days, and 30 days after randomization
|
Incidence of rebleeding and infection in the two groups within 3 days, 7 days, and 30 days after randomization |
3 days, 7 days, and 30 days after randomization
|
|
Incidence of complications
Időkeret: 180 days
|
Incidence of other common complications within 180 days (epilepsy, hydrocephalus, pneumonia, gastrointestinal bleeding, deep vein thrombosis, cardiovascular and cerebrovascular events, etc.) |
180 days
|
|
Incidence of adverse events and serious adverse events
Időkeret: 180 days
|
Incidence of adverse events and serious adverse events in the two groups within 180 days |
180 days
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Tanulmányi szék: Rong Hu, MD, PLA Army Medical University
Publikációk és hasznos linkek
Általános kiadványok
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0. Epub 2010 Jan 5.
- Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005 Jan 29-Feb 4;365(9457):387-97. doi: 10.1016/S0140-6736(05)17826-X.
- Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi: 10.1161/STR.0000000000000069. Epub 2015 May 28.
- Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, Hemphill JC 3rd, Johnson R, Keigher KM, Mack WJ, Mocco J, Newton EJ, Ruff IM, Sansing LH, Schulman S, Selim MH, Sheth KN, Sprigg N, Sunnerhagen KS; American Heart Association/American Stroke Association. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022 Jul;53(7):e282-e361. doi: 10.1161/STR.0000000000000407. Epub 2022 May 17. No abstract available.
- Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Munoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25.
- Pradilla G, Ratcliff JJ, Hall AJ, Saville BR, Allen JW, Paulon G, McGlothlin A, Lewis RJ, Fitzgerald M, Caveney AF, Li XT, Bain M, Gomes J, Jankowitz B, Zenonos G, Molyneaux BJ, Davies J, Siddiqui A, Chicoine MR, Keyrouz SG, Grossberg JA, Shah MV, Singh R, Bohnstedt BN, Frankel M, Wright DW, Barrow DL; ENRICH trial investigators; ENRICH Trial Investigators. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. N Engl J Med. 2024 Apr 11;390(14):1277-1289. doi: 10.1056/NEJMoa2308440.
- Beck J, Fung C, Strbian D, Butikofer L, Z'Graggen WJ, Lang MF, Beyeler S, Gralla J, Ringel F, Schaller K, Plesnila N, Arnold M, Hacke W, Juni P, Mendelow AD, Stapf C, Al-Shahi Salman R, Bressan J, Lerch S, Hakim A, Martinez-Majander N, Piippo-Karjalainen A, Vajkoczy P, Wolf S, Schubert GA, Hollig A, Veldeman M, Roelz R, Gruber A, Rauch P, Mielke D, Rohde V, Kerz T, Uhl E, Thanasi E, Huttner HB, Kallmunzer B, Jaap Kappelle L, Deinsberger W, Roth C, Lemmens R, Leppert J, Sanmillan JL, Coutinho JM, Hackenberg KAM, Reimann G, Mazighi M, Bassetti CLA, Mattle HP, Raabe A, Fischer U; SWITCH study investigators. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial. Lancet. 2024 Jun 1;403(10442):2395-2404. doi: 10.1016/S0140-6736(24)00702-5. Epub 2024 May 15.
- Correction to: ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for Brain Hemorrhage: A Multicenter Randomized Controlled Trial. Stroke. 2017 Nov;48(11):e335. doi: 10.1161/STR.0000000000000153. No abstract available.
- Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE III Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 9;393(10175):1021-1032. doi: 10.1016/S0140-6736(19)30195-3. Epub 2019 Feb 7.
- Teo KC, Fong SM, Leung WCY, Leung IYH, Wong YK, Choi OMY, Yam KK, Lo RCN, Cheung RTF, Ho SL, Tsang ACO, Leung GKK, Chan KH, Lau KK. Location-Specific Hematoma Volume Cutoff and Clinical Outcomes in Intracerebral Hemorrhage. Stroke. 2023 Jun;54(6):1548-1557. doi: 10.1161/STROKEAHA.122.041246. Epub 2023 May 22.
- Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993 Jul;24(7):987-93. doi: 10.1161/01.str.24.7.987.
- Sondag L, Schreuder FHBM, Boogaarts HD, Rovers MM, Vandertop WP, Dammers R, Klijn CJM; Dutch ICH Surgery Trial Study Group, part of the CONTRAST consortiumdagger. Neurosurgical Intervention for Supratentorial Intracerebral Hemorrhage. Ann Neurol. 2020 Aug;88(2):239-250. doi: 10.1002/ana.25732. Epub 2020 Apr 30.
- Pinho J, Costa AS, Araujo JM, Amorim JM, Ferreira C. Intracerebral hemorrhage outcome: A comprehensive update. J Neurol Sci. 2019 Mar 15;398:54-66. doi: 10.1016/j.jns.2019.01.013. Epub 2019 Jan 14.
- GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Cerebrovaszkuláris rendellenességek
- Agyi betegségek
- Központi idegrendszeri betegségek
- Idegrendszeri betegségek
- Érrendszeri betegségek
- Szív-és érrendszeri betegségek
- Patológiás folyamatok
- Vérzés
- Intrakraniális vérzések
- Kóros állapotok, jelek és tünetek
- Agyvérzés
- Műtéti eljárások, operatív
- Idegsebészeti eljárások
- Kraniotómia
Egyéb vizsgálati azonosító számok
- Neurosurg 05
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .